In Vitro Anti- Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657 | Zendy

Junko Akada | Zendy; Mutsunori Shirai | Zendy; Kenji Fujii | Zendy; Kiwamu Okita | Zendy; Teruko Nakazawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Anti- Helicobacter pylori Activities of New Rifamycin Derivatives, KRM-1648 and KRM-1657

Author(s) -

Junko Akada,

Mutsunori Shirai,

Kenji Fujii,

Kiwamu Okita,

Teruko Nakazawa

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.5.1072

Subject(s) - helicobacter pylori , microbiology and biotechnology , rifamycin , amoxicillin , antimicrobial , bacteria , biology , antibiotics , genetics

The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 microgram/ml, respectively) than those of amoxicillin and rifampin for H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research